T
The420Guy
Guest
GW Pharmaceuticals will be marketing Sativex, GW's cannabis-based medicinal
extract product through Bayer Healthcare AG ("Bayer") in Europe by this
summer, with Canada to follow later.
GW has just completed setting up a series of webpages that provide high
quality information about conditions appropriate for use of the product,
complete with references to the studies that support the use of medical
cannabis by medical condition.
The webpages start at:
Improving Patients' Lives | Jazz Pharmaceuticals
Listed medical conditions, being updated on a regular basis, now include:
AIDS Wasting Syndrome
Arthritis
Multiple Sclerosis
Nausea Associated with Cancer Chemotherapy
Pain
Phantom Limb Pain
Spinal Cord Injury
Anti-Tumour Effects
Asthma
Crohn's Disease and Ulcerative Colitis (Inflammatory Bowel Disease)
Depression and Mental Illness
Neuroprotection/Degenerative Diseases
Epilepsy/Seizure Disorder
Obstetrics and Gynaecology
Glaucoma
Appetite Stimulation/Cachexia
Migraine
Cannabis and Drug Withdrawal Treatment
Intractable Breathlessness
extract product through Bayer Healthcare AG ("Bayer") in Europe by this
summer, with Canada to follow later.
GW has just completed setting up a series of webpages that provide high
quality information about conditions appropriate for use of the product,
complete with references to the studies that support the use of medical
cannabis by medical condition.
The webpages start at:
Improving Patients' Lives | Jazz Pharmaceuticals
Listed medical conditions, being updated on a regular basis, now include:
AIDS Wasting Syndrome
Arthritis
Multiple Sclerosis
Nausea Associated with Cancer Chemotherapy
Pain
Phantom Limb Pain
Spinal Cord Injury
Anti-Tumour Effects
Asthma
Crohn's Disease and Ulcerative Colitis (Inflammatory Bowel Disease)
Depression and Mental Illness
Neuroprotection/Degenerative Diseases
Epilepsy/Seizure Disorder
Obstetrics and Gynaecology
Glaucoma
Appetite Stimulation/Cachexia
Migraine
Cannabis and Drug Withdrawal Treatment
Intractable Breathlessness
